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ABSTRACT: For genetic counselling of a woman on
familial breast cancer, an accurate evaluation of the
probability that she carries a germ-line mutation is
needed to assist in making decisions about genetic-
testing.
We used data from eight collaborating centres
comprising 618 families (346 breast cancer only, 239
breast or ovarian cancer) recruited as research families
or counselled for familial breast cancer, representing a
broad range of family structures.  Screening was
performed in affected women from 618 families for
germ-line mutations in BRCA1 and in 176 families for
BRCA2 mutations, using different methods including
SSCP, CSGE, DGGE, FAMA and PTT analysis
followed by direct sequencing.  Germ-line BRCA1
mutations were detected in 132 families and BRCA2
mutations in 16 families.  The probability of being a
carrier of a dominant breast cancer gene was
calculated for the screened individual under the
established genetic model for breast cancer
susceptibility, first, with parameters for age-specific
penetrances for breast cancer only [7] and, second,
with age-specific penetrances for ovarian cancer in
addition [20].  Our results indicate that the estimated
probability of carrying a dominant breast cancer gene
gives a direct measure of the likelihood of detecting
mutations in BRCA1 and BRCA2.  For breast/ovarian
cancer families, the genetic model according to Narod
et al. [20] is preferable for calculating the proband’s
genetic risk, and gives detection rates that indicate a
50% sensitivity of the gene test.  Due to the
incomplete BRCA2 screening of the families, we
cannot yet draw any conclusions with respect to the
breast cancer only families.
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INTRODUCTION
The awareness of genetic predisposition to
breast cancer has increased tremendously since
the identification of the two highly penetrant
breast and ovarian cancer genes, BRCA1 and
BRCA2 [19,29].  Women with a family history
of breast cancer are particularly concerned about
their own risk, thus creating a greater demand for
risk assessment and genetic counselling as well
as for genetic testing.  Mutations in BRCA1 or
BRCA2 account for the majority of high risk
families in which the segregation of a dominant
high-penetrance susceptibility gene has quite
clearly manifested itself in multiple cases of
breast cancer over several generations of close
relatives [13].  Only a small proportion of
families with less striking family history and with
isolated early onset breast cancer can also be
attributed to mutations in these genes, except in
founder populations with recurrent mutations
[1,10,14,16,18,21,28].  Mutation screening of
affected family members is the preferred method
used to quantify risk in high risk families since
the identification of a functionally relevant
mutation will permit differentiation between gene
carrier and non-gene carrier status and thus more
accurate quantification of risk for unaffected
family members.  Women with an inherited
mutation in either BRCA1 or BRCA2 have an
equally high lifetime risk of about 80 percent for
breast cancer, where BRCA1 confers a higher
risk for ovarian cancer and BRCA2 for male
breast cancer [8,9,26].  Those who are non-
carriers in a family with an inherited mutation
will have the population risk of developing breast
cancer which is 8%–12% in western European
countries.  Screening for mutations is, however,
still a technically demanding and labor-intensive
task and gene testing is usually only offered to
persons with a more than threefold increase in
risk compared to the general population [15].
For genetic counselling about familial breast
cancer, an accurate evaluation of the probability
that a woman carries a mutation is needed before
making decisions about genetic-testing.  Some
estimates of the prior probabilities for detecting a
mutation in certain family types defined by
number and age at diagnosis of breast and
ovarian cancer were reported and have recently
been updated [13,23].  However, they do not
account for families which may actually be
harbouring mutations in a highly penetrant
susceptibility gene, but are presenting a family
history that does not provide conclusive evidence
for the involvement of such a gene.  One
commonly employed model for estimating breast
cancer risk, specifically for women with a family
history of the disease, is based on the Cancer and
Steroid Hormone (CASH) study data set.  Claus
et al. [5] have used these data to construct
detailed tables that predict the cumulative risk of
breast cancer over a given time interval based on
age at onset of one or two affected first- and/or
second-degree relatives.  However, the Claus
tables do not consider the complete pedigree
structure, i.e., the number and ages of unaffected
relatives and the exact genealogical relationship
between the proband and her affected relatives.
A more sophisticated method of risk prediction
is implemented in the software package
LINKAGE [17] and allows the estimation of the
proband’s genetic risk under a particular genetic
model, given her family history.  This calculation
takes into account the entire pedigree
information, including family size, relationships,
ages and disease phenotypes of all members and
has been shown to provide more accurate risk
estimation particularly in families with smaller
numbers of affected members [22].  The
magnitude of the estimated genetic risks depends
upon the assumed genetic model and can
therefore vary appreciably when different
penetrance estimates are used.
In a previous study of 60 families, we
investigated whether the carrier probability
calculated for the youngest affected member
according to one genetic model is useful for
identifying high-risk families and found that all
families with detected BRCA1 mutations showed
carrier probabilities above 0.6 [3].  We were
therefore interested to apply the different models
empirically to estimate the probability of carrying
a breast cancer susceptibility gene for women
with a family history of the disease and compare
these estimates with the outcome of mutation
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screening in a larger series of families from
cancer genetics clinics.
MATERIALS AND METHODS
Families
We used data from eight collaborating centres
of a European Union Demonstration Project, four
located in the United Kingdom (Aberdeen,
London, Manchester, Southampton), and one
each in France (Paris), Germany (Heidelberg),
Italy (Pisa) and Norway (Oslo).  Families were
recruited as research families or counselled for
familial breast cancer at the cancer genetics
clinics or both.  Different criteria for inclusion
were used by each centre, thus the families
represent a broad range of family structures.
Detailed pedigree information was obtained
through the proband (consultand) and, in some
instances, extended through contact with related
family members.  All diagnoses of cancer were
verified from pathology reports where
possible.  Blood samples were obtained from an
affected proband (if the consultand) or an
affected family member.
Mutation analysis
Screening for mutations in BRCA1 was
performed in the affected proband or affected
family member in each of the 618 families
included in this study.  Mutation screening in
BRCA2 was completed in 176 of these
families.  Different screening methods were
employed in the different laboratories to detect
sequence variants and included single strand
conformation polymorphism (SSCP),
conformation-sensitive gel electrophoresis
(CSGE), denaturing gradient gel electro-
phoresis
 (DGGE), fluorescent assisted
missense analysis
 (FAMA), and protein
truncation test (PTT).  The entire coding
sequence and exon-intron boundaries of the
BRCA1 gene were amplified from genomic DNA
using PCR.  Each variant exon was then
reamplified and analysed non-radioactively with
an automatic sequencer.  All analyses demon-
strating mutations were repeated for
verification.  For other purposes of this study,
only functionally relevant mutations were
considered and individuals with missense
mutations of unproven clinical significance were
not considered “positive” for germ-line
pathogenic mutations [6,25].
Statistical analysis
As a measure of genetic risk without genotype
data, the probability of being a carrier of a mutant
allele (BRCA1 or BRCA2 or other dominant
genes) was calculated for the affected individual
screened in each family under the established
genetic model for breast cancer derived by Claus
et al. [4] with the MLINK component of the
linkage analysis package LINKAGE [17].  We
performed the calculations first using the
penetrance parameters employed by Easton et al.
[7] and then using those adapted by Narod et al.
[20] for the analysis of Breast Cancer Linkage
Consortium data.  Under the Easton model, breast
cancer susceptibility is conferred by an
autosomal dominant allele, with population
frequency 0.0033, such that breast cancer risk is
67% by age 70 years.  Under the Narod model,
breast cancer susceptibility confers a breast
cancer cumulative risk that is 71% by age 70
years and an ovarian cancer cumulative risk that
is 42% by age 70 years.  To implement this
model in LINKAGE, family members were
assigned to either 14 liability classes [7] or 21
liability [20] defined by (i) affection status, (ii)
site of cancer (breast or ovarian), and (iii) age at
cancer diagnosis or at last observation, using the
seven age groups < 30, 30–39, 40–49, 50–59, 60–
69, 70–79, and ≥ 80 years.  Unaffected males
were assigned to the liability class of females
unaffected up to age 29, approximately
equivalent to being of unknown carrier
status.  Females affected with both breast and
ovarian cancer and males affected with breast
cancer were assigned to the liability class of
females affected in the youngest age group, thus
maximizing their probability of being gene
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carriers.  Under the Easton model, females with
ovarian cancer diagnosed at any age were also
assigned to this liability class.  The calculated
carrier probability is supposed to predict the
likelihood of finding either BRCA1 or BRCA2
mutations.  Thus, we assumed a combined gene
frequency of mutant BRCAx alleles of 0.0033, as
in the CASH model derived by Claus et al. [4].
Frequencies and proportions of individuals
with detected mutations were descriptively
presented by grouping according to participating
centre, family type and estimated carrier
probability.
RESULTS
The 618 families studied included 346 families
with female breast cancer only, 239 families with
female breast and ovarian cancer and 17 families
with only ovarian cancer.  A further 12 breast
cancer only and four breast and ovarian cancer
families included male breast cancer
(Table 1).  The mean age at diagnosis in families
was 46.3 years for female breast cancer (range
between 19 and 79 years), 53.2 years for male
breast cancer (range between 29 and 73 years)
and 52.7 years for ovarian cancer (range between
14 and 80 years).  Due to the different types of
families recruited by the eight centres, the mean
carrier probability of probands screened by each
centre showed a range between 0.30 and 0.82
calculated with the Easton model and between
0.22 and 0.73 with the Narod model (Figure 1).
Germline mutations in BRCA1 were detected
in 132 families (21.4%) overall, and in 35
(10.1%) families with female breast cancer only,
88 (36.8%) breast-ovarian cancer families, 8
(47.1%) families with ovarian cancer only and 1
(8.3%) family with male breast cancer
(Table 2).  The majority of the mutations were
chain terminating, including 95 frameshift
deletions/insertions, 21 nonsense mutations, 4
splice variant mutations, and there were 12
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Fig. 1.  A histogram of the mean carrier probability calculated for the screened patient under the genetic model
according to (a) Easton et al. (1993)  and (b) Narod et al. (1995)   for each of the participating centres.
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missense mutations considered to be functionally
relevant.  Of the families analysed for BRCA2,
sixteen families harboured BRCA2 mutations,
including 7 in breast cancer only families, 6 in
breast-ovarian cancer families, and 3 in families
with male breast cancer.
As expected the proportions of BRCA1 and
BRCA2 mutations detected is higher in the
higher ranges of carrier probability of the
screened individual (Table 3).  For breast cancer
only families, BRCA1 mutations were detected in
34% or 26% (according to Easton or Narod
model) of those who have a greater than 95%
probability of carrying a mutant allele in a
susceptibility gene whereas mutations were found
in about 5% among those with carrier
probabilities less than 40%.  In the case of breast-
ovarian families, BRCA1 mutations were
detected in 48% or 49% (according to Easton or
Narod model) of those with carrier probabilities
above 95% and 25% or 16% of those with carrier
probabilities below 40%.  The gradient of the
proportion with BRCA1 mutations is apparent for
breast cancer only families and does not differ for
carrier probabilities according to the two genetic
models.  For breast-ovarian cancer families
(including ovarian cancer only families), it
appears that the carrier probabilities calculated
Table 1
Distribution of  families in different family types by participating centrea
Family type All labs ABD LON MAN SOUTH PARIS HD PISA OSLO
BC only, female only
No. of cases
1 99 0 7 2 89 1 0 0 0
2-3 158 15 19 12 63 17 19 9 4
4+ 89 11 2 18 2 14 31 5 6
BC/OV, female only
No. of cases
1 2 0 0 0 0 2 0 0 0
2-3 93 10 3 24 6 31 7 6 6
4+ 144 8 3 41 5 45 32 3 7
OV only 17 3 0 8 0 2 0 2 2
BC only, +male BC 12 2 0 0 2 4 4 0 0
BC/OV, +male BC 4 1 0 0 0 2 1 0 0
Total 618 50 34 105 167 118 94 25 25
aABD Aberdeen, LON London, MAN Manchester, SOUTH Southampton, HD Heidelberg
Table 2
BRCA1 and BRCA2 mutations detected in different family types (all centres)
Family type BRCA1 screened BRCA1 mutation BRCA2 screened BRCA2 mutation
BC only, female only
No. of cases
1 99 2 1 0
2-3 158 19 35 3
4+ 89 14 48 4
BC/OV, female only
No. of cases
2-3 93 29 34 1
4+ 144 59 44 5
OV only 17 8 3 0
BC only, +male BC 12 1 9 2
BC/OV, +male BC 4 0 4 1
618 132 176 16
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using the Narod model correlate better with the
proportion of BRCA1 mutations detected.
BRCA2 mutation analysis has not been
completed for all families.  Thus, although the
largest proportion of mutations was detected in
those who have carrier probabilities above 95%,
the correlation with decreasing carrier probability
is not clearly discernible.
The graphs of the proportions of BRCA1 and
BRCA2 mutations by smaller ranges of carrier
probability show clearly that probability of
detecting a gene mutation increases with
increasing carrier probability, particularly in
breast cancer only families (Figures 2 and 3).
When we consider only families with 4 or
more breast cancer cases diagnosed under the age
of 60 years, regardless of the occurrence of
ovarian cancer, the carrier probability of the
screened patient still ranges between 0.29 and 1.0
with a mean of 0.92 when using the Easton
model and between 0.16 and 1.0 with a mean of
0.88 for the Narod model.  The proportion of
detected mutations is above 40% in patients with
carrier probabilities greater than 95% and below
30% in those with carrier probabilities between
60% and 90% (Figure 4).  Even in these families
with multiple cases of breast cancer, there is
clearly a correspondence between the proportion
of mutations detected and the calculated carrier
probability.
DISCUSSION
We investigated descriptively whether gene
carrier probabilities, given family history,
calculated for families referred to cancer genetics
clinics, predicts the likelihood of finding a
mutation in one of the breast cancer susceptibility
genes.  The series of families studied ranged from
single early onset cases to large families with
multiple affected members and reflects the type
of families that could be counselled in any cancer
genetics clinic.  Several different techniques were
used for mutation screening in this study.  Since
all these methods are conventionally employed at
cancer genetics clinics and have similar reported
sensitivity levels, we felt that the combined
results could reflect the experience of other
centres.  
In the interpretation of the results, we are
limited by the fact that mutation screening for
BRCA2 was not completed in all families.  Thus,
the estimated proportion of mutations detected
will always be lower than expected even when
we take into account the sensitivity of the
screening methods and the existence of further
highly penetrant breast cancer susceptibility
genes.  Based on 237 families with at least four
cases of breast cancers aged under 60 years at
diagnosis collected by the Breast Cancer Linkage
Consortium, Ford et al. [13] estimated that 80%
Table 3
Detection of BRCA1 and BRCA2 mutations in families by carrier probability and family type
Carrier probability Breast only families Breast-ovarian families
(range) n BRCA1 mutations BRCA2 mutations n BRCA1 mutations BRCA2 mutations
n (%) n  (%) n (%)  n  (%)
 Easton model
0.95-1.0 29 10  (34) 3  (10) 122 59  (48) 7  (6)
0.9-0.95 35 5  (14) 2  (6) 55 17  (31) 0
0.8-0.9 39 6  (15) 1  (3) 36 13  (36) 0
0.6-0.8 65 5  (8) 1  (2) 18 1  (6) 0
0.4-0.6 34 3  (9) 2  (6) 9 1  (11) 0
0-0.4 156 7  (4) 0 20 5  (25) 0
 Narod model
0.95-1.0 34 9  (26) 4  (12) 77 38  (49) 7  (9)
0.9-0.95 17 3  (18) 1  (6) 39 18  (46) 0
0.8-0.9 30 5  (17) 0 26 12  (46) 0
0.6-0.8 44 3  (7) 1  (2) 29 12  (41) 0
0.4-0.6 46 6  (13) 2  (4) 31 7  (23) 0
0-0.4 187 10  (0.05) 1  (0.005) 58 9  (0.16) 0
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Fig. 2.  Two histograms showing the proportion of (i) BRCA1 mutation , (ii) BRCA2 mutation  and (iii) without
mutation  detected in screened patients from 260 “breast-ovarian cancer” families (including ovarian cancer only
families) in different ranges of carrier probability calculated under the genetic model according to (a) Easton et al.
(1993) and (b) Narod et al. (1995).
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Fig. 3.  Two histograms showing the proportion of (i) BRCA1 mutation  , (ii) BRCA2 mutation  and (iii) without
mutation  detected in screened patients from 358 “breast cancer only” families in different ranges of carrier
probability calculated under the genetic model according to (a) Easton et al. (1993) and (b) Narod et al. (1995).
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Fig. 4.  Two histograms showing the proportion of (i) BRCA1 mutation  , (ii) BRCA2 mutation  and (iii)
without mutation  detected in screened patients from 97 families with four or more breast cancer cases under 60
years of age in different ranges of carrier probability calculated under the genetic model according to (a) Easton et
al. (1993) and (b) Narod et al. (1995).
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of hereditary breast-ovarian cancer families are
attributed to BRCA1 and 15% to BRCA2.  For
breast cancer only families, BRCA1 and BRCA2
contribute 28% and 37%, respectively, with 35%
unexplained by the identified genes.  Since
BRCA1 explains the majority of breast-ovarian
cancer families, we can interpret our results more
incisively with respect to the breast-ovarian
cancer families rather than to the breast cancer
only families.
For breast-ovarian cancer families, the
correlation between the detection of a germ-line
mutation in BRCA1 and the estimated probability
of being carrier of a susceptibility gene for the
screened proband is clearly better based on the
genetic model according to Narod et al. [20].
This can be seen by noting that for each of the
ranges of carrier probability, the proportion
detected is approximately 50% of the mean
carrier probability of that range, and this is
relatively constant over all groups.  For example,
for the carrier probability range of 0.9 to 0.95, the
proportion of mutations detected was 0.46
(Table 3).  This is not unexpected since the
Narod model incorporates age-specific
penetrances for ovarian cancer as well.  This also
indicates a sensitivity of the gene test of about
50%.  This corresponds to the expected detection
rate if we assumed the estimated sensitivity of
63% and the contribution of BRCA1 to breast-
ovarian cancer families of 80% from the data of
the Breast Cancer Linkage Consortium
[13].  Since these estimates are likely to be
similar for ovarian cancer specific families [24],
we included the ovarian cancer only families
when examining the group of breast-ovarian
cancer families.
For breast cancer only families, our present
data do not show an apparent difference in the
correlation between detecting a germ-line
mutation in BRCA1 or BRCA2 and the estimated
probability that the screened proband is a carrier
of a susceptibility gene, based on the two genetic
models employed.  The two genetic models differ
only in the age-specific penetrances of breast
cancer whereby, in the Narod model, an older
case of breast cancer is assigned a lower
probability of being a carrier of a mutant
gene.  We cannot, however, draw any
conclusions with respect to the breast cancer
families before BRCA2 mutation screening is
completed in a larger proportion of these
families.
We show that the calculation of the probability
of being carrier of a susceptibility gene is a more
refined method of risk assessment when we focus
on a set of families defined by number and age of
affected family members.  In the 97 high-risk
families with four or more breast cancer cases
diagnosed under the age of 60 years, there were 9
families in which the estimated carrier
probability of the screened patient was below
0.6.  Mutations in BRCA1 were not detected in
any of these families.  As we would have
expected, the multiple cases in these families
were more often second and third degree relatives
of one another and less likely to be first degree
related.
The estimation of the probability of being
carrier of a dominant breast cancer susceptibility
gene, given family history, provides a common
measure for all types of families being counselled
and gives a direct measure for the likelihood of
detecting mutations in BRCA1 and BRCA2 if the
contribution of these genes for the specific family
type involved (breast cancer only or breast and
ovarian cancer) is taken into account.  For
families with breast and ovarian cancer
occurrence, the Claus model with parameters
according to Narod et al. [20] is the preferred
genetic model for the calculation of the proband’s
genetic risk.  As we have discussed previously,
the carrier probability can be reduced
considerably when the correlation between
phenotypes and genotypes is imperfect [3].  For
the computation, this situation arises not only
with incomplete penetrance of the genotype but
also when an obligate carrier is affected with
other cancers which are known to be BRCA1
or BRCA2 associated but which are not
accounted for in the assumed genetic model
[2,9,11,27].  Therefore, the accuracy of the
estimated carrier probability as a measure of
genetic risk will always depend upon the
accuracy of the pedigree data and the assumed
genetic model.
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At present, it is not possible to derive gene
specific risks using the LINKAGE software
employed.  Estimates of gene frequency of
BRCA1 and age-specific penetrances for BRCA1
and BRCA2 are available and estimates of gene
frequency for BRCA2 are being generated from
several population-based studies [10,12,
13,28].  In the future, we shall be able to evaluate
the usefulness of estimates of gene specific risks
for decision-making in genetic diagnosis.
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